TDM concentration targets (when used) for once-daily dosed aminoglycosides used by the respondents
| . | Peak concentration (mg/L) . | Respondentsa . | Trough concentration (mg/L) . | Respondentsa . |
|---|---|---|---|---|
| Amikacin | 41 (26–60) | 47 | 3 (2–5) | 59 |
| Gentamicin | 12 (10–17.5) | 37 | 1 (0.5–1.5) | 122 |
| Tobramycin | 12 (10–23.8) | 7 | 2 (1.3–2) | 12 |
| . | Peak concentration (mg/L) . | Respondentsa . | Trough concentration (mg/L) . | Respondentsa . |
|---|---|---|---|---|
| Amikacin | 41 (26–60) | 47 | 3 (2–5) | 59 |
| Gentamicin | 12 (10–17.5) | 37 | 1 (0.5–1.5) | 122 |
| Tobramycin | 12 (10–23.8) | 7 | 2 (1.3–2) | 12 |
The preferred aminoglycoside was gentamicin for 55%, amikacin for 40% and tobramycin for 5% of those who provided data on aminoglycoside use. TDM values are shown as median (IQR).
aNumber of persons that gave a target value for TDM.
TDM concentration targets (when used) for once-daily dosed aminoglycosides used by the respondents
| . | Peak concentration (mg/L) . | Respondentsa . | Trough concentration (mg/L) . | Respondentsa . |
|---|---|---|---|---|
| Amikacin | 41 (26–60) | 47 | 3 (2–5) | 59 |
| Gentamicin | 12 (10–17.5) | 37 | 1 (0.5–1.5) | 122 |
| Tobramycin | 12 (10–23.8) | 7 | 2 (1.3–2) | 12 |
| . | Peak concentration (mg/L) . | Respondentsa . | Trough concentration (mg/L) . | Respondentsa . |
|---|---|---|---|---|
| Amikacin | 41 (26–60) | 47 | 3 (2–5) | 59 |
| Gentamicin | 12 (10–17.5) | 37 | 1 (0.5–1.5) | 122 |
| Tobramycin | 12 (10–23.8) | 7 | 2 (1.3–2) | 12 |
The preferred aminoglycoside was gentamicin for 55%, amikacin for 40% and tobramycin for 5% of those who provided data on aminoglycoside use. TDM values are shown as median (IQR).
aNumber of persons that gave a target value for TDM.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
